J-M Michot

Internal Medicine pract. at Gustave Roussy, in Early Drug Unit. News therapies solutions to be proposed to all pts with hard-to-treat diseases. Tweet my owns.

[J-M Michot @MichotJM]

@benoit_donckele 1-3 pour le HAC

[Gustave Roussy @GustaveRoussy]

De l’or plein les yeux pour les enfants hospitalisés de @GustaveRoussy grâce à la @PAFofficiel, marraine d’@ImagineforMargo 🤩

Mille mercis à la #PatrouilleDeFrance pour ce moment exceptionnel offert aux enfants et aux soignants de Gustave Roussy ❤️

#SeptembreEnOr

[FabriceAndre @FAndreMD]

Proteomics (1463 prots) identified LIF levels in the plasma as biomarker of resistance to anti-PD1 Ab. Findings validated in an independant cohort of 292 pts. Circulating LIF correlated with 3ry lymphoid structures in tumor. A study from @GustaveRoussy https://t.co/LxQ8saQlqu

[J-M Michot @MichotJM]

@y_loriot @drcmassard @GustaveRoussy thank you to @drcmassard for linking up a unique huge team in onco & hematology !and for having bring the best P1 therapies in DITEP for pts at @GustaveRoussy

[Blood Journals Portfolio @BloodPortfolio]

Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study https://t.co/mrZxFi3bwc

[soria @jsoriamd]

Oncology phase I trials have been referred to as ‘toxicity trials’. The last decade has demonstrated that phase I trials have ORRs of ~20%, (this is within the range of ORRs of several FDA -approved drugs, making them potentially valid therapeutic options
https://t.co/Lt24YRXQWd

[J-M Michot @MichotJM]

Knowing better about new drugs means above all better understanding how healthy organs work. Thnks to @DrMichaelColli1 and GI team for this comprehensive report in @EXCLIJournal
Emblematic P1 + GI expert coop for
@GustaveRoussy @Hopital_Bicetre @UnivParisSaclay @LillyPad

[EXCLI Journal @EXCLIJournal]

#Notch inhibitors induce diarrhea, hypercrinia and secretory cell #metaplasia in the #humanColon

The authors of https://t.co/2PR5DK4ssX studied #intestinal #toxicity of the Notch inhibitor #LY3039478 in cohort study.

@Hopital_Bicetre @UnivParisSaclay @GustaveRoussy @LillyPad

[EXCLI Journal @EXCLIJournal]

#Notch inhibitors induce diarrhea, hypercrinia and secretory cell #metaplasia in the #humanColon

The authors of https://t.co/2PR5DK4ssX studied #intestinal #toxicity of the Notch inhibitor #LY3039478 in cohort study.

@Hopital_Bicetre @UnivParisSaclay @GustaveRoussy @LillyPad

[ELLyE l’Association #Lymphomes #LLC @AssoELLyE]

#VACCINATION #antiCOVID19
Les points essentiels pour les personnes ayant ou ayant eu un #lymphome
Mise à jour au 11 février 2021

[The Lancet @TheLancet]

2 years ago, we published a special theme issue, #LancetWomen, highlighting how gender bias has stalled women’s advancement in science, medicine, and🌎health. Today, we highlight key milestones and reinforce our commitment to #genderequality.

[Imoca MACIF Santé Prévoyance @ImocaMacif]

Complètement fou ! 🤩

Charlie et APIVIA franchissent la ligne d'arrivée du @VendeeGlobe à la première place au terme d'une course dingue.
Un seul mot ce soir : MERCI Charlie ! 🙏

@ApiviaMutuelle | @Apivia_courtage | @MacifAssurances

[J-M Michot @MichotJM]

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited https://t.co/7Rdt7sqQmR

[C. Thieblemont @c_thieblemont]

SDmax captures lymphoma dissemination. SDmax and TMTV are independent prognosticators and identify high-risk DLBCL patients at baseline. A REMARC @LysaLymphoma ancillary analysis by AS Cottereau et al. see our publication at @Annals_Oncolgy https://t.co/AGlEWuW0u6

[FabriceAndre @FAndreMD]

Something is happening on the side of pancreatic cancer (300 000 death per y): PARP inh, Ras Inh, adj therapies, early detect/ctDNA. Transformation is ongoing
A top priority for Funding agencies and philanthropies (https://t.co/BJYXzGR4WG @FondationARC @DenisBrogniart @ALJ)

[Thilo J. Zander @ThiloZander]

Have you ever heard of anti-ROR1? A new MOA to keep in mind for upcoming #ASH20:
VLS-101, ROR1 antibody drug conjugate (ADC) w/MMAE - Phase 1 trial in pts w/recurrent Mantle Cell and #DLBCL & Still small n but impressive results. Congrats, @michaelwangmd

[J-M Michot @MichotJM]

#ASH20 : Yi Lin: CAR-T for R/R MM study CRB-401 longer FU of P1 with idecabtagene vicleucel raise the median OS = 34.2 mo in a highly prett / selected pop of pts. In the P2 the median OS is 19.4 mo and median PFS 8.8 mo. Safety update unravel frequent neutropenia (G3/4: 88.7%)

[Simon Rule @rule_simon]

Looks very good

[J-M Michot @MichotJM]

#ASH20 Sham Mailankody: FIH anti-bcma ALLO-CAR-T cells in r/r multiple myeloma; 90% treated in 5 days of enrollement ! Dose cells responses / up-to 60% ORR => Most than encouraging.

[Neeraj Agarwal, MD, FASCO @neerajaiims]

In @NEJM ➡️ Cancer pts receiving immunosuppressive Rx may shed viable #COVID19 virus for 60 days after infection.👇Quarantine guidelines need revision. Pertinent research with huge implications on our practices. 👉🏻 https://t.co/WV1TMmLPNF @mini_kamboj & team @SocietyofMSKCC

[J-M Michot @MichotJM]

#ASH20 #Phase1 #CTCL targeted by multiple cytokine targets drug BNZ-1 (ILs 15-2-9). Extensively prett pts pop.(median of 5 L). No safety major pb. Response rate 53%. Encouraging phases 1 results indicating CTCL is an immunologic disease to treat with IO new agents.